05 FDA decisions to watch in the third quarter of 2026 Summary: The second quarter of 2026 marked a turning point for the Food and Drug Administration. Follow BiopharmaDive’s insight of the top 05 important decisions of the FDA under new leadership Click to see the full article Novartis commits $1.1B upfront to take Myricx […]